Market Overview

Pfizer Confirms License of Families of Spinal Muscular Atrophy Quinazoline Drug Program from Repligen

Share:
Related RGEN
PreMarket Prep Recap, March 20: Major Volatility At Friday's Close And Why Disney Is In For A Big Quarter
10 Stocks That Rallied Four Days, Then Sold Off Yesterday
Repligen to Participate in –4th Annual Craig-Hallum Institutional Investor Conference (GuruFocus)
Related PFE
The Current State Of The Breast Cancer Treatment Space
Exclusive: Corium CEO Gives The Scoop On His Company's Latest Alzheimer's Data
S&P 500, Nasdaq Hit Record Highs; FANGs Bare Their Teeth (Investor's Business Daily)

Repligen Corporation (NASDAQ: RGEN) announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

Posted-In: News FDA

 

Related Articles (RGEN + PFE)

View Comments and Join the Discussion!